Although cell therapy shows great promise as a new therapeutic strategy for heart failure, its precise mechanisms remain unclear. Furthermore, the advantages of cell therapy over conventional cytokine therapy have yet to be clarified. This study was designed to compare the functional improvement achieved by cell therapy and cytokine therapy in both ischemic and nonischemic heart failure experimental models. Ischemic heart failure was induced by ligating the left anterior descending artery, and nonischemic heart failure was induced by an IP injection of doxorubicin, respectively, in mice. After establishing the heart failure models, mice were randomly given a single intramyocardial injection of 2 × 10 5 c-kit-positive bone marrow stem cells (cell therapy), hepatic growth factor (cytokine therapy), or PBS injection only (control). In the ischemic heart failure model, both cell therapy and cytokine therapy increased the vessel density significantly, inhibited apoptosis of myocytes, and decreased the fibrotic area in the ischemic myocardium, which resulted in a significant increase in the survival rate and enhancement of the cardiac function of these mice (p < 0.05 vs. control therapy). In the nonischemic heart failure model, significant increases in the survival rate and cardiac function were achieved by cell therapy (p < 0.05 vs. control therapy), but not by cytokine therapy, although cytokine therapy inhibited the fibrosis and apoptosis of the cardiomyocytes. Both cell therapy and cytokine therapy are alternative treatments for ischemic heart failure. However, cell therapy is more effective for the treatment of nonischemic heart failure than cytokine therapy achieved by the administration of a single growth factor.
INTRODUCTION
autologous bone marrow-derived stem cells, myoblasts, or other cells, has been found to improve regional perfusion and cardiac function in various experimental heart Despite remarkable progress in drug therapy, percutaneous catheter intervention, and surgical coronary artery failure models (5, 8, 12, 13, 21) , and in limited preliminary clinical trials of patients with ischemic heart failure bypass grafting, the prognosis of patients with end-stage heart failure remains very poor. Cardiac transplantation (3, 6, 22, 25, 29) . Studies have found that the implanted stem cells from bone marrow can survive and be prolif-is currently the treatment of choice for patients with endstage heart failure, but it is limited by the shortage of erated and differentiated into endothelial cells or cardiomyocytes in situ, contributing to functional improve-donors. Cytokine-based therapy, achieved by the direct administration of protein or gene transfer with vascular ment of the injured heart by rebuilding the damaged myocardium and cardiac vessels (8, 21) . However, there endothelial growth factor, basic fibroblast growth factor, or hepatic growth factor (HGF), was developed as new is no consensus on the plasticity of bone marrow stem cells, and most studies have found that myogenic or en-treatment for heart failure, especially end-stage ischemic heart failure (4, 10, 15, 23, 24) . However, the effectiveness dothelial differentiation rarely occurs, if at all (1, 16, 19, 26) . Therefore, it is doubtful that the in situ differentia-of cytokine-based therapy for the functional improvement of heart failure has not yet been shown in random-tion or proliferation of implanted cells contributes remarkably to functional improvement of the injured heart. ized control trials (4, 10, 24) .
Recently, cell-based therapy, achieved by delivering Conversely, it is speculated that the cytokines produced by these implanted cells play a more important role than failure model), and an additional IP injection of 20 µg HGF on days 2, 4, and 6, respectively (HGF group). their differentiation and proliferation. This indicates that the improvement in cardiac function achieved by cell-
The control mice were given a single intramyocardial injection of PBS only (PBS group). based therapy is through a paracrine mechanism (11). However, the precise mechanisms of cell-based therapy
The intramyocardial injection was performed with a 31-gauge needle under direct vision, as described pre-for heart failure remain unclear, and the advantages of cell-based therapy over conventional cytokine-based viously (13). In the ischemic heart failure model, the ischemic myocardium was injected at four points (10 therapy have not been proven.
Using both ischemic heart failure and nonischemic µl/point), immediately after ligation of the left anterior descending artery. In the nonischemic heart failure heart failure mouse models, we investigated the mechanisms of cell-based and cytokine-based therapies for model, the mice were anesthetized, a left thoracotomy was done, and the left ventricular wall was injected at myocardial repair, and compared their advantages for improving cardiac function.
four points (10 µl/point).
MATERIALS AND METHODS

Echocardiography Animals
Cardiac function was measured before treatment, then 7, 14, and 28 days after treatment, by a single ob-GFP-transgenic mice (C57BL6/Tg14) were kindly server blind to the treatment regimen, with echocardiogprovided by Masaru Okabe (Genome Research Center, raphy using a HDI-5000 ultrasound machine (Philips, Osaka University, Osaka) (20), and bred in the Animal Netherlands) equipped with a 15-MHz probe (13). After Center of Yamaguchi University. Wild-type C57BL/6 the induction of light general anesthesia, the hearts were mice were purchased from Japan SLC (Shizuoka, Jaimaged two-dimensionally in long-axis views at the pan). We used 12-to 15-week-old mice and all experilevel of the greatest left ventricle (LV) diameter. We ments were approved by the Institutional Animal Care measured the systolic and diastolic LV areas at the same and Use Committee of Yamaguchi University.
time. This view was used to position the M-mode cursor Establishing the Ischemic and Nonischemic Heart perpendicular to the LV anterior and posterior walls.
Failure Models
The LV dimension was measured at the end-diastole dimension (LVEDD) and at the end-systole dimension The ischemic heart failure model was established in (LVESD). The dimensions were calculated from the avwild C57/BL6 mice by ligating the left anterior descenderage measurements of three selected continuous beats. ing artery with 9-0 prolene under direct vision, as de-
The percentage of LV fraction shortening (LVFS%) was scribed previously (13). After ligating the left anterior calculated as: (LVEDD − LVESD)/LVEDD × 100 (%). descending artery, mice were randomly given cell therapy, cytokine therapy, or control therapy as described Histological Evaluation below.
After the final echocardiography assessment on day The nonischemic heart failure model was established 28, the mice were killed and the hearts were harvested. by giving the mice an IP injection of doxorubicin 2.5
To detect the development of microvessels, 5-µm-thick mg/kg twice weekly for 3 weeks (total, 15 mg/kg). One frozen sections were stained with alkaline phosphatase week after the completion of doxorubicin administrausing an indoxyl tetrazolium method, and then countertion, mice were randomly given cell therapy, cytokine stained with eosin (13). The number of microvessels was therapy, or control treatment, as described below.
counted under a microscope with 200× magnification by Cell Therapy and Cytokine Therapy a single observer blind to the treatment regimen. At least 10 different fields were selected randomly from three The mice treated with cell therapy were given a single intramyocardial injection of bone marrow stem cells, independent slides with about 1 mm apart from each heart tissue, and the mean number of microvessels per as described previously (13). Briefly, c-kit-positive bone marrow stem cells were collected from GFP-transgenic field was calculated for statistical analysis. Azan staining was also done to assess collagen fiber mice and separated by a magnetic cell sorter. Freshly collected cells were suspended at a density of 5 × 10 6 accumulation in the infarcted region (13). An image of the LV area on each slide was prepared, and the area of cells/ml in phosphate-buffered saline. The mice were given an intramyocardial injection of 2 × 10 5 newly iso-fibrosis and the total LV area of each image were measured using the Image-Pro Plus version 5.1.2 (Media lated bone marrow stem cells (BMSC group).
The mice treated with cytokine therapy were given Cybernetics Inc., Carlsbad, CA, USA). The percentage of the fibrotic area was calculated as fibrotic area/total an intramyocardial injection of 20 µg HGF on day 0 (immediately after LAD ligation in the ischemic heart area of LV wall × 100. Measurements were done on at least three separate sections with about 1 mm apart from group. Furthermore, the LVFS% was significantly higher in the BMSC and HGF groups than in the PBS each heart tissue, and the averages of each heart were used for statistical analysis. group 14 and 28 days after treatment (p < 0.05) ( Fig.  2A) . Relatively, the LVEDD was significantly lower in For the mice given cell therapy, the survival of implanted bone marrow stem cells was visualized directly the BMSC and HGF groups than in the PBS group 14 and 28 days after treatment (p < 0.05) ( Fig. 2A ). under conventional fluorescence microscopy. The endothelial and myogenic differentiations of surviving bone
In the nonischemic heart failure model, the LVFS% was about 25% at the baseline (day 0), without signifi-marrow stem cells were identified by immunostaining with monoclonal antibodies of mouse anti-cardiac myo-cant differences among the groups (Fig. 2B ). The LVFS% in the BMSC group increased slightly after the sin heavy chain and rat anti-VE-cadherin (Pharmingen), respectively. Positively stained cells were detected after implantation of bone marrow stem cells, but it did not increase in either the HGF or PBS groups after treat-incubation with R-PE-conjugated secondary antibodies. ment, and there was no difference between these two TUNEL Assay groups (Fig. 2B ). Thereafter, the LVFS% was signifi-To observe the degree of apoptotic cell death, a tercantly higher in the BMSC group than in the HGF and minal dUTP nick end-labeling (TUNEL) assay was per-PBS groups 28 days after treatment (p < 0.05) ( Fig. 2B ). formed in 5-µm-thick frozen sections using Apoptosis Interestingly, although the LVESD did not differ be-Detection Kits (R&D System Inc., Minneapolis, MN, tween the HGF and BMSC groups, the LVEDD de-USA). Sections were also stained with DAPI (4′,6creased slightly in the BMSC group whereas it increased diamidino-2-phenylindole) to visualize nuclei. The apogradually in the HGF group, resulting in a significantly ptosis index was calculated as the number of TUNELlower LVEDD in the BMSC group than in the HGF positive myocyte nuclei per 1000 nuclei. At least 20 group, 28 days after treatment (p < 0.05) ( Fig. 2B ). different fields were selected for random counting from three independent slides of each sample, and the aver-Microvessel Density ages were used for statistical analysis.
To measure the induction of therapeutic angiogenesis, we counted the microvessels in the LV myocar-Statistical Analysis dium. We counted microvessel density from the area of All data are expressed as means ± SD. Echocardioinfarction and the infarction border area for the ischemic graphic data were compared by two-way ANOVAs for heart failure model, but from the LV anterior wall for repeated measures, and group differences at specific the nonischemic heart failure area. In the ischemic heart time points were then assessed by a Bonferroni t-test.
failure model, the mean microvessel count per field in Other data were assessed by one-way ANOVAs, folthe LV myocardium 28 days after treatment did not diflowed by a Bonferroni t-test. A value of p < 0.05 was fer significantly between the BMSC and HGF groups considered significant.
( (Fig. 3B ). tively. A significantly higher survival rate was observed in both the BMSC and HGF groups in the ischemic heart
Area of Fibrosis failure model (p < 0.05 vs. PBS group) ( Fig. 1A) . How-In the ischemic heart failure model, Azan staining ever, in the nonischemic heart failure model, the surshowed that the fibrotic area in the infarcted myocarvival rate was increased significantly in the BMSC dium was significantly smaller in the BMSC and HGF group (p < 0.05 vs. PBS group), but not in the HGF groups than in the PBS group 28 days after treatment group (Fig. 1B ).
( Fig. 4A ). In the nonischemic heart failure model, the Cardiac Function fibrotic area in the LV myocardium was also significantly smaller in the BMSC and HGF groups than in the In the ischemic heart failure model, echocardiography showed that the LVFS% was about 15% at the base-PBS group 28 days after treatment (Fig. 4B ). Although the fibrotic area was slightly bigger in the HGF group line (day 0), without significant differences among the groups (Fig. 2A) . The LVFS% increased after treatment than in the BMSC group in the nonischemic heart failure model, there was no difference between these two in both the BMSC and HGF groups, but not in the PBS groups, in either the ischemic or nonischemic heart fail-osin-positive bone marrow stem cells and the host cardiomyocytes (data not shown). The pattern of survival and ure models.
differentiation of the implanted bone marrow stem cells Apoptosis of Cardiomyocytes did not differ obviously between the ischemic and nonischemic heart failure models. Apoptosis of cardiomyocytes was estimated by TUNEL staining (Fig. 5A ). As we did not perform dou-DISCUSSION ble staining, apoptosis of the cardiomyocytes was assessed by microscopic examination of the myocyte-Various mechanisms of functional repair by cell therspecific morphological structure only. Quantitative analapy and cytokine therapy have been explored to treat ysis indicated that there were significantly fewer heart failure. These include the improvement of myocar-TUNEL-positive cells in the LV myocardium in the dial ischemia by inducing angiogenesis, the direct pro-BMSC and HGF groups than in the PBS group, in both tection of myocytes against apoptosis, the improvement the ischemic and nonischemic heart failure models ( Fig. of LV remodeling, and the rebuilding of new functional 5B, C). However, there was no significant difference bemyocardium (5,7-9,12-14,18,21,27,28). However, the tween the BMSC and HGF groups.
precise mechanism of functional repair is still poorly understood. Furthermore, it is possible that cell therapy Survival, Differentiation, and Interaction of Implanted and cytokine therapy for functional repair of heart fail-Bone Marrow Stem Cells ure involve different mechanisms, and are dependent on the pathogenesis and phases of heart failure. This study We examined the survival, differentiation, and interaction of implanted bone marrow stem cells in the was designed to compare the effectiveness of cell-based therapy and cytokine-based therapy for functional im-BMSC group. Consistent with our previous findings (13), these bone marrow stem cells survived well after provement of ischemic and nonischemic heart failure, and to find their mechanical differences. implantation, and formed a cell cluster in the left ventricular wall, in both the ischemic and nonischemic heart
In this study, cell therapy was done by the intramyocardial implantation of bone marrow stem cells because failure models (Fig. 6A, B ). Some of these bone marrow stem cells stained positively for VE-cadherin, and some autologous bone marrow-derived cells are one of the most popular cell sources used in experimental and clin-of the VE-cadherin-positive bone marrow stem cells were localized in the vessel wall, indicating endothelial ical studies (3, 5, 6, 8, 12, 13, 21, 22, 25, 29) . Cytokine therapy was induced by the delivery of HGF, a multifunc-differentiation and incorporation (Fig. 6C ). Furthermore, very few of the surviving bone marrow stem cells also tional cytokine, which has been shown to effectively induce angiogenesis, inhibit apoptosis, and improve re-stained positively for cardiac myosin, which indicated rare myogenic differentiation (Fig. 6D ). However, there modeling of the injured heart (7,9,14,18,27,28). Our results showed that the cardiac function and sur-was no distinct gap junction formation between the my-vival of mice with experimental ischemic heart failure myocytes was also decreased by both therapies. Although some of these values were slightly worse in the was improved significantly by the implantation of bone marrow stem cells or the administration of HGF. We mice that received HGF than in those that received bone marrow stem cell implantation, the differences were not also found that the microvessel density was increased, but the fibrotic area was decreased by both therapies significant. All the results indicated that cell therapy and cytokine therapy had similar potency for achieving func-in the ischemic heart failure model. The apoptosis of ischemic heart failure model. The LVFS% was significantly higher, but the LVEDD was significantly lower, in the BMSC and HGF groups than in the PBS group after 14 and 28 days of treatment. There were no differences in any of these measurements between the BMSC and HGF groups. (B) Time course changes of LVFS%, LVEDD, and LVESD in the nonischemic heart failure model. The LVFS% was significantly higher, but the LVEDD was significantly lower, in the BMSC group than in the HGF and PBS groups 28 days after treatment. In the ischemic heart failure model, the microvessel density was significantly higher in the BMSC and HGF groups than in the PBS group, but it did not differ significantly between the BMSC group and the HGF group. (B) There were no significant differences among the BMSC HGF, and PBS groups in the nonischemic heart failure model. tional repair of ischemic heart failure, by inducing thera-pair of the heart with nonischemic heart failure. We found that neither bone marrow stem cell implantation peutic angiogenesis, protecting myocytes against apoptosis, and improving LV remodeling.
nor HGF administration increased the microvessel density of LV myocardium. This suggests that the func-Interestingly, the implantation of bone marrow stem cells enhanced the cardiac function and survival of mice tional improvement of nonischemic heart failure by cell therapy seems not to be related to the enhancement of with drug-induced nonischemic heart failure, but the administration of HGF did not. The dissociated response therapeutic angiogenesis. We also examined myocyte apoptosis and the fibrotic between cell therapy and cytokine therapy is probably related to their different mechanisms for functional re-area in mice with nonischemic heart failure. Myocyte apoptosis and the fibrotic area in the LV myocardium other mechanisms contribute to the dissociated response between cell therapy and cytokine therapy in functional decreased after the implantation of bone marrow stem cells and the administration of HGF, which suggested repair of nonischemic heart failure. The rebuilding of new functional myocardium by the the beneficial effects of both therapies for functional repair of nonischemic heart failure. As we already men-differentiation and maturation of implanted bone marrow stem cells is a likely mechanism. Although there is tioned, the survival and cardiac function of mice with nonischemic heart failure was only improved by cell im-still no consensus (1, 8, 13, 16, 19, 21, 26) , it is possible that bone marrow stem cells could be differentiated into plantation, but not by HGF administration. The reason for these contradictory findings remains unclear. As the structural and functional cardiomyocytes. In this study, the expression of cardiac myosin in bone marrow stem fibrotic area and the myocyte apoptosis were higher in the HGF-treated mice than in the mice treated with cell cells was found rarely 28 days after implantation into either the ischemic or nonischemic hearts. Furthermore, therapy, it is possible that the inhibition of apoptosis and fibrosis by HGF are negligible, and insufficient to no distinct formation of a gap junction was detected between the myogenic differentiated bone marrow stem increase global cardiac function significantly, although this explanation is unconvincing. It is more likely that cells and the host cardiomyocytes, which indicated no obvious rebuilding of new functional myocardium by hanced the survival and contractile capacity of cardiomyocytes (26) . Thus, it is possible that the continuous the differentiation and maturation of implanted bone marrow stem cells. However, these bone marrow stem release of growth factors from implanted cells will increase the contractive potency of the host myocardium, cells survived well after implantation, and formed cell clusters within the left ventricular wall. It was reported and thereby contribute to the functional improvement of heart failure. that cell therapy can limit ventricular dilatation by preserving extracellular matrix homeostasis (2) . As drug-Although the benefits of HGF for myocardial repair in acute ischemic heart failure models are well recog-induced nonischemic heart failure is characterized by advanced ventricular dilatation, the survival of im-nized (9, 14, 27, 28) , the effectiveness of HGF for functional repair has yet to be clarified in nonischemic heart planted cells in myocardium may inhibit ventricular dilatation in the nonischemic heart failure model. In fact, failure. It was reported that 3 weeks of treatment with HGF improved cardiac function in a late-stage nonische-our data showed that the left ventricular end-diastole dimension was significantly less in the mice given cell mic heart failure model in hamsters (18) . Moreover, HGF improved the proliferation of myocardial progeni-therapy than in those given cytokine therapy. Moreover, our recent investigation found that bone marrow cells tor cells (28) . Conversely, another recent investigation found that cardiac function in cardiomyopathy-induced could produce various growth factors, which directly en- capacity of the host myocardium. Although we lack con-Sylven, C.; Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene clusive evidence, cell-based therapy is probably more therapy in patients with stable severe angina pectoris A effective for the treatment of nonischemic heart failure randomized double-blind placebo-controlled study: The than cytokine therapy with single growth factor delivery. express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis
